Translational Development Acquisition (TDACU) Preferred Stock Liabilities (2024 - 2026)

Translational Development Acquisition has reported Preferred Stock Liabilities for 3 years, with the latest figure at $183.3 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Stock Liabilities rose 4.02% year-over-year to $183.3 million; the trailing twelve-month figure through Mar 2026 stood at $183.3 million (up 4.02% YoY), and the FY2025 full-year result was $181.7 million, up 4.19% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $183.3 million, up from $181.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $183.3 million in Q1 2026, with the low at $174.4 million in Q4 2024.
• Historically, Preferred Stock Liabilities has averaged $178.9 million across 3 years, with a median of $179.0 million in 2025.
• Annual changes were most pronounced in 2025 — Preferred Stock Liabilities climbed 4.19% — and 2026, when it gained 4.02%.
• Translational Development Acquisition's Preferred Stock Liabilities stood at $174.4 million in 2024, then gained by 4.19% to $181.7 million in 2025, then grew by 0.89% to $183.3 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $183.3 million (Q1 2026), $181.7 million (Q4 2025), and $179.9 million (Q3 2025), per Business Quant data.